Literature DB >> 19302035

A routine method for the quantification of the novel antimycotic drug posaconazole in plasma using liquid chromatography-tandem mass spectrometry.

Michael Vogeser1, Christina Rieger, Helmut Ostermann, Ute Spöhrer.   

Abstract

BACKGROUND: Posaconazole is now widely used for prophylaxis of invasive fungal infections in immunocompromised patients. The pharmacokinetic properties of the drug argue for therapeutic monitoring, but so far described analytical methods have shortcomings with respect to application in a routine setting. The aim of our work was to develop an analytical method suitable for routine use.
METHODS: Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was used. For sample preparation, protein precipitation followed by on-line solid phase extraction was used. SCH 56984, a posaconazole related compound provided by the manufacturer of posaconazole, was used as internal standard.
RESULTS: The method was characterized by short hands-on time and an analytical run time of four minutes. Validation data demonstrated acceptable analytical performance.
CONCLUSIONS: LC-MS/MS with on-line solid phase extraction for sample preparation allows the implementation of a convenient and reliable method for pharmacokinetic monitoring of posaconazole.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19302035     DOI: 10.1515/CCLM.2009.129

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  3 in total

1.  Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing.

Authors:  Bertrand Rochat; Andres Pascual; Benoît Pesse; Frédéric Lamoth; Dominique Sanglard; Laurent A Decosterd; Jacques Bille; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-10-04       Impact factor: 5.191

2.  Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin.

Authors:  Laurent Arthur Decosterd; Bertrand Rochat; Benoît Pesse; Thomas Mercier; Frédéric Tissot; Nicolas Widmer; Jacques Bille; Thierry Calandra; Boris Zanolari; Oscar Marchetti
Journal:  Antimicrob Agents Chemother       Date:  2010-09-20       Impact factor: 5.191

3.  Fungal Prophylaxis with a Gastro-Resistant Posaconazole Tablet for Patients with Hematological Malignancies in the POSANANTES Study.

Authors:  Pierre Peterlin; Cécile Chauvin; Steven Le Gouill; Morgane Pere; Marie Dalichampt; Thierry Guillaume; Alice Garnier; Maxime Paré; Amandine Le Bourgeois; Philippe Moreau; Patrice Chevallier; Guillaume Deslandes; Thomas Gastinne
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.